Novo-Nordisk A/S (NVO) Earnings Date & Reports
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more
NVO is expected to report earnings to fall 20.84% to 82 cents per share on August 05
Novo Nordisk (NVO) Q1 2026 Earnings Recap: Provision Reversal Fuels Reported Beat
Key Takeaways
- Novo Nordisk reported Q1 2026 sales of DKK 96.8 billion, up 32% at constant exchange rates (CER), driven by a DKK 26.8 billion (USD 4.2 billion) non-cash reversal of a 340B provision.
- Adjusted sales (excluding 340B) fell 4% at CER to DKK 70.1 billion, with GLP-1 volume growth offsetting pricing pressures.
- Reported operating profit surged 65% at CER to DKK 59.6 billion; adjusted operating profit declined 6% at CER to DKK 32.9 billion.
- Diluted EPS rose 67% to DKK 10.91; adjusted diluted EPS dipped 3% to DKK 6.63.
- Full-year 2026 guidance raised: adjusted sales and operating profit growth now -4% to -12% at CER (prior: -5% to -13%).
- Wegovy pill sales hit DKK 2.3 billion, nearly double expectations, signaling strong demand.
Earnings Context and Why It Matters
Novo Nordisk, a leader in diabetes and obesity treatments with blockbuster GLP-1 drugs like Ozempic and Wegovy, released its first-quarter 2026 results on May 6, 2026. This report is pivotal amid intense competition from Eli Lilly and pricing headwinds in the U.S., including the 340B Drug Pricing Program (a U.S. federal initiative requiring discounts for safety-net providers). Investors scrutinized adjusted metrics excluding the one-time provision reversal, as they reveal underlying demand for GLP-1 therapies amid a booming obesity market. Strong volume growth could affirm Novo Nordisk's market dominance, while guidance updates signal confidence in navigating challenges like lower realized prices and exclusivity losses.
Novo Nordisk's fiscal quarters align with calendar quarters, covering January 1 to March 31, 2026. Reported sales reached DKK 96,823 million, surpassing consensus estimates around DKK 69-72 billion, with 32% growth at CER versus prior year. This was boosted by the reversal of a DKK 26.8 billion provision tied to the U.S. 340B program, a non-cash item with no cash flow impact.
Adjusted sales, excluding the reversal, were DKK 70,063 million, down 4% at CER, as lower U.S. prices (US operations down 11% adjusted) offset GLP-1 volume gains. Reported operating profit hit DKK 59,618 million (up 65% CER), beating expectations near DKK 31.7 billion; adjusted fell 6% CER to DKK 32,858 million, above company-compiled forecasts of DKK 28.7 billion.
Diluted EPS was DKK 10.91 (up 67%), versus ADR consensus ~$0.87 (equivalent ~DKK 6 DKK/share at prevailing rates); adjusted EPS DKK 6.63 (down 3%). Key metrics: gross margin 85.9% reported (80.6% adjusted); Obesity care sales up 22% adjusted CER; Wegovy up strongly, Ozempic DKK 27.8 billion adjusted. Guidance improved on higher GLP-1 expectations.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.
Market Reaction and Investor Sentiment
Shares of Novo Nordisk rose over 2% in extended trading post-release, reaching around $46, reflecting relief over the adjusted profit beat and raised guidance despite pricing woes. Sentiment focused positively on Wegovy pill's "strongest-ever" U.S. launch (>2 million total prescriptions) and resilient GLP-1 demand, overshadowing adjusted declines. However, U.S. pricing pressures tempered enthusiasm, with the stock up modestly amid broader market gains.
Forward Outlook and Key Factors to Monitor
Following Q1, Novo Nordisk raised its 2026 outlook to -4% to -12% growth for adjusted sales and operating profit at CER, from prior -5% to -13%, citing stronger GLP-1 sales expectations. This assumes stable business conditions and currency rates as of late April 2026. Free cash flow guidance holds at DKK 36-46 billion, supporting DKK 37.7 billion in recent shareholder returns.
Investors should watch U.S. operations, where pricing from the MFN (most-favored-nation) agreement and 340B litigation resolution weigh on margins, offset by Wegovy higher-dose (HD) rollout and pill uptake (self-pay subscriptions, telehealth via Hims & Hers). International expansion—Wegovy in >55 countries, Ozempic 2.0 mg launches—drives volume, with obesity care up 44% CER in international markets.
Pipeline catalysts include R&D investments (DKK 22.4 billion returned to growth); approvals like Wegovy 7.2 mg (EU/U.S.), Awiqli diabetes pen; phase 3 readouts (etavopivat for sickle cell, 27% VOC reduction). Monitor competition from Eli Lilly's Mounjaro/Zepbound, supply ramp-up, and gross margin trends (80.6% adjusted Q1). Upcoming: Q2 results August 5, 2026; Capital Markets Day September 20-21.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsMajor